{"id":"sdr-pep-rifampicin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Gastrointestinal disturbances"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Drug interactions (enzyme induction)"}]},"_chembl":{"chemblId":"CHEMBL374478","moleculeType":"Small molecule","molecularWeight":"822.95"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rifampicin is a well-established antibiotic that binds to bacterial RNA polymerase and blocks transcription, making it highly effective against Mycobacterium tuberculosis and other mycobacteria. The SDR-PEP (Solid Dispersion Rifampicin with Polyethylene Glycol) formulation is designed to improve bioavailability and provide sustained drug release, potentially enhancing therapeutic efficacy and reducing dosing frequency in tuberculosis treatment.","oneSentence":"SDR-PEP Rifampicin is a sustained-release formulation of rifampicin that inhibits bacterial RNA polymerase to suppress mycobacterial protein synthesis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:33:44.262Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tuberculosis (pulmonary and extrapulmonary)"},{"name":"Drug-resistant tuberculosis"}]},"trialDetails":[{"nctId":"NCT06222372","phase":"NA","title":"Novel Interventions and Diagnostic Tests for Leprosy","status":"RECRUITING","sponsor":"Annemieke Geluk","startDate":"2020-03-04","conditions":"Leprosy","enrollment":1100},{"nctId":"NCT05406479","phase":"PHASE2","title":"Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy (Phase 2)","status":"COMPLETED","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2022-07-14","conditions":"Leprosy","enrollment":313},{"nctId":"NCT05597280","phase":"PHASE3","title":"Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy","status":"RECRUITING","sponsor":"Institute of Tropical Medicine, Belgium","startDate":"2023-03-22","conditions":"Leprosy","enrollment":124000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"SDR-PEP Rifampicin","genericName":"SDR-PEP Rifampicin","companyName":"Institute of Tropical Medicine, Belgium","companyId":"institute-of-tropical-medicine-belgium","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SDR-PEP Rifampicin is a sustained-release formulation of rifampicin that inhibits bacterial RNA polymerase to suppress mycobacterial protein synthesis. Used for Tuberculosis (pulmonary and extrapulmonary), Drug-resistant tuberculosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}